Harvard Infectious Diseases In Adults 2026 (Videos + PDFs)

The Harvard Infectious Diseases In Adults 2026 program provides a comprehensive, expert-led review of the most current developments in diagnosing and managing complex infectious diseases. The curriculum covers a wide array of high-yield topics, including antimicrobial stewardship, emerging fungal and viral infections, HIV management, and multidisciplinary approaches to challenging cases such as endocarditis, bone infections, and mycobacterial diseases.
Course Date: May 4, 2026 – May 8, 2026

Infectious Diseases in Adults 2026 provides state-of-the-art approaches for the prevention, diagnosis, and management of infectious diseases: common, challenging, rare, and emerging.

State-of-the-Art Approaches to Prevention, Diagnosis, and Treatment of Infectious Diseases in Adults
Infectious Diseases in Adults 2026 is LIVE STREAMED with on-demand access available for 90 days after the course.
This comprehensive CME program, now in its 50th year, ensures attendees are current with state-of-the-art approaches to prevention, diagnosis, and treatment of infectious diseases. Updates, best practices, and new guidelines are presented by nationally recognized ID experts and master clinicians. Education is practical and results-driven:

Optimal decision-making across a range of common and unusual infectious diseases
Newer antimicrobials and treatment strategies for highly resistant infections
Prevention and treatment of infections in immunocompromised hosts
Update on antifungal diagnostics and therapy
State-of-the-art and multidisciplinary approaches to common infections
Clinical approaches to complex, rare, and “don’t-miss” infections
New, evolving, emerging, and re-emerging infectious diseases
Infections in persons with substance use disorder
What’s new in HIV prevention and management
The latest on COVID-19, including long COVID
Adult vaccinations in 2026

As revised treatment strategies, new diagnostic tests, and guidelines are presented, they are coupled with specific recommendations for incorporating these updates into your day-to-day work.
In addition to being live streamed, all sessions will be recorded and placed in the online course library, enabling registrants to view them at their convenience. Recordings will be available for viewing for 90 days after the conclusion of the course. All live streaming and recorded sessions are eligible for AMA PRA Category 1 Credits™ and other relevant credits. (Note: Evaluations must be completed within 60 days of the conclusion of the course to receive CME credit.)
Highlights of the 2026 Program
Expanded Case-Based and Problem-Solving Education
The 2026 program features an expanded range of interactive, case-based, and problem-solving education. The formats are engaging, and attendees are encouraged to pose questions to our national experts in live question-and-answer sessions following the lectures and the multidisciplinary workshops.
Our speakers and panelists include not only ID experts, but those from fields such as pharmacy, surgery, radiology, cardiology, pulmonology, and addiction medicine, thereby providing a 360-degree context for the understanding of ID treatment and patient care.
Our ten multidisciplinary workshops include complicated urinary tract and intra-abdominal infections, resistant Gram-positive and Gram-negative infections, management of endocarditis and cardiac device infections, musculoskeletal infections, and nontuberculous mycobacterial infections.
Treating Highly Resistant Infections, including:

MRSA and VISA (vancomycin-intermediate Staph aureus)
Extended-spectrum beta-lactamase (ESBL)-producing Gram-negative rods
Carbapenemase-producing Gram-negative rods, including NDM-1 metallo-beta-lactamase-producing organisms
Vancomycin-resistant enterococci (VRE)
Resistant fungal infections, including Aspergillus, other molds, and resistant Candidal infections
Nontuberculous mycobacteria (NTM)

Common Infectious Diseases: Updates in Prevention, Diagnosis, and Treatment, including:

Respiratory viral infections, including COVID-19
New and updated vaccine guidance
Infections in the expanding populations of immunocompromised hosts
Infections in persons with substance use disorder
Infections of travelers and foreign-born persons
Systemic fungal infections
Native and device-related orthopedic infections
Central nervous system (CNS) infections
Native and prosthetic valve endocarditis, and cardiac device infections
Ear, nose, and throat (ENT) and eye infections
Skin and soft tissue infections
Bronchiectasis and pneumonia
HIV and its infectious and noninfectious complications
PEP (Post-Exposure Prophylaxis) and PrEP (Pre-Exposure Prophylaxis) to prevent HIV infection
Sexually transmitted infections (STIs), including mpox and PEP for prevention of STIs
Hepatitis B and C infections
Tick- and mosquito-borne infections
Clostridioides difficile infection, the gut microbiome, and pre- and probiotics
Complicated urinary tract infections
Intra-abdominal infections

Challenging, Rare, and Emerging Infectious Diseases, including:

Highly pathogenic avian flu
Re-emergence of vaccine-preventable diseases, including poliomyelitis
Pulmonary and extrapulmonary non-tuberculous (“atypical”) mycobacteria, including Mycobacterium abscessus
Global infectious diseases of clinical importance

Clinical Decision-Making
Hear directly from world-renowned specialists and master clinicians on their approach and decision-making criteria for:

Selecting the best antimicrobial and duration of treatment
Rapid detection and empiric treatment of life-threatening infectious diseases
Choosing between inpatient and outpatient treatment, and between intravenous and oral antimicrobials
Optimizing empiric antimicrobial therapy: what to start, and how and when to de-escalate

Our multidisciplinary talks and workshops incorporate safety, quality, and practice improvement in infectious diseases, including:

Antimicrobial stewardship to prevent resistance and reduce cost
Early inpatient ID consultations to improve outcomes
Strategies for management of infection in persons who inject drugs (PWID)